Home/Pipeline/Tiprelestat

Tiprelestat

Pulmonary Arterial Hypertension (PAH)

Phase 2Active

Key Facts

Indication

Pulmonary Arterial Hypertension (PAH)

Phase

Phase 2

Status

Active

Company

tiakis Biotech, tiakis Biotech

About tiakis Biotech

Tiakis Biotech is a private, clinical-stage biotech company headquartered in Kiel, Germany, founded in 2000 (with a noted 2020 date in some records, suggesting a corporate restructuring). The company is developing Tiprelestat, a pioneering anti-inflammatory and tissue-protective drug based on the human protein Elafin, targeting Pulmonary Arterial Hypertension and postoperative inflammatory complications. With a leadership team boasting multi-disciplinary experience and support from government R&D programs, Tiakis aims to shift treatment paradigms towards preventive, root-cause focused therapies. The company is currently pre-revenue, advancing its lead candidate through clinical development.

View full company profile

About tiakis Biotech

View full company profile

Therapeutic Areas

Pulmonary Arterial Hypertension Postoperative Complications

Other Pulmonary Arterial Hypertension (PAH) Drugs

Drug	Company	Phase	Status
YUTREPIA™ (treprostinil) inhalation powder	Liquidia	Approved	Commercial
LIQ861 (treprostinil) inhalation powder	Liquidia	Phase 3	Completed
L606 (liposomal treprostinil) injection	Liquidia	Preclinical	Active
NTP42	ATXA Therapeutics	Phase 1	Active; Orphan Drug Designation from FDA and EMA. Phase 1 results published.
Transdermal Treprostinil Prodrug Patch	Corsair Pharma	Pre-clinical	Active
Anti-EMAP II monoclonal antibody	Allinaire Therapeutics	Pre-clinical	Active
Seralutinib	Chiesi	Phase 3	Active
Sotatercept	Merck	Phase 3	Active
TPIP (Treprostinil Palmitil Inhalation Powder)	Insmed	Phase 2b	Active
Ralinepag	United Therapeutics	Phase 3	Active (ADVANCE CAP)
Beraprost MR	United Therapeutics	Phase 3	Active (ISABELA)
CS1	Cereno Scientific	Phase II	Active; Phase IIa completed, Phase IIb in preparation